Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
肿瘤
/
DNA损伤
细胞周期 肿瘤表观遗传和基因调控
/ 拓扑异构酶 / Pirarubicin/吡柔比星

Pirarubicin/吡柔比星 {[allProObj[0].p_purity_real_show]}

货号：A154529 同义名： THP; NSC-333054

Pirarubicin是一种蒽环类抗生素，通过抑制拓扑异构酶 II 来发挥抗肿瘤作用，适用于各种癌症的研究。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Pirarubicin/吡柔比星 化学结构 CAS号：72496-41-4
Pirarubicin/吡柔比星 化学结构
CAS号：72496-41-4
Pirarubicin/吡柔比星 3D分子结构
CAS号：72496-41-4
Pirarubicin/吡柔比星 化学结构 CAS号：72496-41-4
Pirarubicin/吡柔比星 3D分子结构 CAS号：72496-41-4
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Pirarubicin/吡柔比星 纯度/质量文件 产品仅供科研

货号：A154529 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Adv. Funct. Mater., 2025, 2500696. Ambeed. [ A245395 ]
• JACS, 2025. Ambeed. [ A505336 ]
• Sci. Adv., 2025, 11(13): eadr0006. Ambeed. [ A152627 ]
• ACS Appl. Mater. Interfaces, 2025, 17(12): 18046-18058. Ambeed. [ A739356 , A171817 ]
• Food Res. Int., 2025, 116191. Ambeed. [ A1452012 ]
更多 >
产品名称 Topo I ↓ Topo II ↓ Topo IV ↓ Topoisomerase ↓ 其他靶点 纯度
Ellagic acid ✔ 98%
β-Lapachone ✔ 99%+
(s)-10-hydroxycamptothecin ✔ 98+%
Camptothecin ++

Topo I, IC50: 0.68 μM

 		98%
Betulinic acid ++

Eukaryotic topoisomerase I, IC50: 5 μM

 		98%
Topotecan ++++

Topo I (DU-145 Luc cells), IC50: 2 nM

Topo I (MCF-7 Luc cells), IC50: 13 nM

 		98%
Irinotecan HCl Trihydrate ✔ 98%
SN-38 ✔ 98%
Levofloxacin hydrate ✔ 98%
Dexrazoxane ✔ 99%+
Ofloxacin ✔ 98+%
Enoxacin ✔ 99%+
Flumequine +

Topo II, IC50: 15 μM

 		98%
Levofloxacin ✔ 97%
Etoposide ✔ 98%
Pefloxacin mesylate dihydrate ✔ 99+%
Marbofloxacin ✔ 98+%
Voreloxin HCl ✔ 98%
Mitoxantrone 2HCl ✔ PKC 98%
Nalidixic acid ✔ 98%
Doxorubicin ✔ 97%
Novobiocin sodium ✔ 95%
Amonafide ✔ 99%+
Pirarubicin ✔ 98%+
Idarubicin HCl +++

Topo II (MCF-7 cells), IC50: 3.3 ng/mL

 		99%+
Genistein ✔ EGFR 98%
Teniposide ✔ 98%
Moxifloxacin ✔ 98%
Ciprofloxacin ✔ 98%
Clinafloxacin ✔ 99%
Gatifloxacin ✔ 98%
Daunorubicin HCl +++

DNA synthesis, Ki: 20 nM

 		98%
Epirubicin HCl ✔ 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Pirarubicin/吡柔比星 生物活性

靶点

  • Topo II
描述 Pirarubicin is a cell cycle nonspecific anthracycline anticancer drug[3]. It interacts with topoisomerase II to inhibit DNA replication. Pirarubicin inhibits the growth of human HeLa and C33A cervical, as well as T-24 bladder cancer cells (IC50s = 29, 52, and 36 ng/ml, respectively)[4]. It inhibits the growth of human Huh7 and MHCC97H liver cancer cells (IC50s = 0.159 and 0.374 μM, respectively)[5]. Pirarubicin also inhibits the growth of M5076 mouse ovarian cancer cells in vitro (IC50 = 0.366 μM) and in vivo in a mouse allograft model when administered at a dose of 2 mg/kg for four days[6].

Pirarubicin/吡柔比星 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03277716 Hepatocellular Carcinoma Non-r... 展开 >>esectable Transarterial Chemoembolization Microwave Ablation 收起 << Not Applicable Recruiting December 30, 2021 China, Beijing ... 展开 >> Cancer Institute &Hospital, Chinese Academy of Medical Sciences Not yet recruiting Beijing, Beijing, China, 100021 Contact: Xiao Li, M.D          China, Fujian The First Affiliated Hospital of Fujian Medical University Recruiting Fuzhou, Fujian, China, 350005 Contact: Zhenyu Lin, M.D.          The tumor hospital of Fujian Province Not yet recruiting Fuzhou, Fujian, China, 350014 Contact: Hailan Lin, M.D          China, Guangdong the First Affiliated Hospital of SunYat-senUniversity Not yet recruiting Guangzhou, Guangdong, China, 510080 Contact: Jiaping Li, M.D          Shenzhen People's Hospital Recruiting Shenzhen, Guangdong, China, 518020 Contact: Yanfang Zhang, M.D.          Peking University Hospital of Shenzhen Recruiting Shenzhen, Guangdong, China, 518036 Contact: Junhui Chen, M.D.          China, Shandong The Second Affiliated Hospital of Shandong University Recruiting Jinan, Shandong, China, 250000 Contact: Yuliang Li, M.D          Shandong Province Hospital Recruiting Jinan, Shandong, China, 250014 Contact: Xin Ye, M.D          the Affiliated Hospital of Medical College Qingdao University Recruiting Qingdao, Shandong, China, 26555 Contact: Zixiang Li, M.D          China, Zhejiang The First Affiliated Hospital of Zhejiang University Not yet recruiting Hangzhou, Zhejiang, China, 310003 Contact: Junhui Sun, M.D. 收起 <<
NCT00131053 Lymphoblastic Leukemia, Acute Phase 2 Unknown September 2011 Japan ... 展开 >> Department of Hematology, Nagoya University Graduate School of Medicine Recruiting Nagoya, Japan, 466-8550 Contact: Fumihiko Hayakawa, MD       bun-hy@med.nagoya-u.ac.jp    Principal Investigator: Fumihiko Hayakawa, MD 收起 <<
NCT02760953 Urinary Bladder Neoplasms Not Applicable Not yet recruiting December 31, 2018 -

Pirarubicin/吡柔比星 参考文献

[1]Liu SY, Song SX, et al. Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line. Chemotherapy. 2010;56(2):101-7.

[2]Sugiyama T, Sadzuka Y, et al. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin. Jpn J Cancer Res. 1999 Jul;90(7):775-80.

[3] Huang H, Chen T, Zhou Y, et al. RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma. Int J Med Sci. 2018;15(14):1648-1657.

[4]Tsuchiya KS, Ishii T, Ikeno S, et al. Inhibition of anchorage-independent growth of tumor cells by IT-62-B, a new anthracycline. J Antibiot (Tokyo). 1997;50(10):853-859.

[5]Huang H, Chen T, Zhou Y, Geng L, Shen T, Zhou L, Zheng S. RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma. Int J Med Sci. 2018 Nov 5;15(14):1648-1657.

[6]Sugiyama T, Sadzuka Y, Nagasawa K, Ohnishi N, Yokoyama T, Sonobe T. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin. Jpn J Cancer Res. 1999;90(7):775-780.

Pirarubicin/吡柔比星 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.59mL

0.32mL

0.16mL

7.97mL

1.59mL

0.80mL

15.93mL

3.19mL

1.59mL

Pirarubicin/吡柔比星 技术信息

CAS号72496-41-4
分子式C32H37NO12
分子量 627.64
SMILES Code O=C1C2=C(C=CC=C2OC)C(C3=C(O)C4=C([C@@H](O[C@@]5([H])C[C@H](N)[C@H](O[C@@]6([H])OCCCC6)[C@H](C)O5)C[C@@](C(CO)=O)(O)C4)C(O)=C31)=O
MDL No. MFCD00869742
别名 THP; NSC-333054
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place, inert atmosphere, 2-8°C
溶解方案

DMSO: 9 mg/mL(14.34 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

Tags: Pirarubicin | 72496-41-4 | THP | Topoisomerase | Autophagy Inducer | Cell Cycle/DNA Damage | Autophagy | Anti-infection | Topoisomerase | Autophagy | Bacterial | Antibiotic | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Pirarubicin/吡柔比星 纯度/质量文件 | Pirarubicin/吡柔比星 亚型比较 | Pirarubicin/吡柔比星 生物活性 | Pirarubicin/吡柔比星 临床数据 | Pirarubicin/吡柔比星 参考文献 | Pirarubicin/吡柔比星 实验方案 | Pirarubicin/吡柔比星 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z